Addressing genetic tumor heterogeneity through computationally predictive combination therapy.
暂无分享,去创建一个
Douglas A Lauffenburger | Boyang Zhao | Justin R Pritchard | Michael T Hemann | D. Lauffenburger | M. Hemann | J. Pritchard | Boyang Zhao
[1] J. Panetta,et al. A mathematical model of drug resistance: heterogeneous tumors. , 1998, Mathematical biosciences.
[2] Jenny Taylor,et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.
[3] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[4] L. Law. Origin of the Resistance of Leukæmic Cells to Folic Acid Antagonists , 1952, Nature.
[5] R. Arceci. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .
[6] D. Lauffenburger,et al. A Systems Model of Signaling Identifies a Molecular Basis Set for Cytokine-Induced Apoptosis , 2005, Science.
[7] S. Lowe,et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors , 2005, Nature Genetics.
[8] R. Aur,et al. Drug dosage and remission duration in childhood lymphocytic leukemia , 1971, Cancer.
[9] Andrew Menzies,et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.
[10] Andrew M. K. Brown,et al. Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.
[11] Goldie Jh,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .
[12] N. Socci,et al. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.
[13] K. Anderson,et al. Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.
[14] C. Swanton. Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.
[15] Douglas A Lauffenburger,et al. A mammalian functional-genetic approach to characterizing cancer therapeutics. , 2010, Nature chemical biology.
[16] Rebecca A Betensky,et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.
[17] R. Arceci. Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells , 2011 .
[18] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[19] S. Lowe,et al. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.
[20] J. Uhm. Clonal selection drives genetic divergence of metastatic medulloblastoma , 2012 .
[21] L. Pusztai,et al. Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.
[22] D. Lauffenburger,et al. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. , 2010, Molecular bioSystems.
[23] J. Goldie,et al. A stochastic model for the origin and treatment of tumors containing drug-resistant cells , 1986, Bulletin of mathematical biology.
[24] G. Gaidano,et al. Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[26] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.
[27] Chen-Hsiang Yeang,et al. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer , 2012, Proceedings of the National Academy of Sciences.
[28] J H Goldie,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.
[29] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[30] J. Carpten,et al. Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.
[31] Luke A. Gilbert,et al. Defining principles of combination drug mechanisms of action , 2012, Proceedings of the National Academy of Sciences.
[32] Ken Chen,et al. Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.
[33] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[34] S. Lowe,et al. INK 4 a / ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p 53 , 1999 .
[35] J H Goldie,et al. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. , 1986, Bulletin of mathematical biology.
[36] R. Palmiter,et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.
[37] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[38] J H Goldie,et al. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.
[39] James R. Downing,et al. Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.
[40] Debyani Chakravarty,et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.
[41] R. Arceci. Clonal selection drives genetic divergence of metastatic medulloblastoma , 2012 .
[42] F. Michor,et al. Evolution of resistance to anti-cancer therapy during general dosing schedules. , 2010, Journal of theoretical biology.
[43] L. Law. Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice. , 1952, Cancer research.
[44] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.